Every 10-Q that Inogen Inc (INGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INGN filings page.
Inogen, Inc. develops and rents respiratory products such as portable and stationary oxygen concentrators, airway clearance devices, and CPAP masks. For the three months ended June 30, 2026, revenue was 95,084 (amounts in thousands), up 3.0% from 92,277, driven by 5.5% growth in sales revenue and 14.8% growth in international sales, partly offset by an 11.8% decline in U.S. rental revenue due to fewer patients on service.
Total gross margin improved to 45.5% from 44.8%, as higher sales volumes and lower component and warranty costs lifted sales margins, while rental margins declined on higher logistics costs per patient. Operating expenses were 48,368, yielding a loss from operations of 5,096, compared with 6,129 a year earlier. Net loss for the quarter was 3,850 (basic and diluted EPS $(0.14)), and for the first six months net loss was 12,174 (EPS $(0.45)).
As of June 30, 2026, Inogen held 87,276 in cash and cash equivalents, 18,263 in marketable securities, and 1,303 in restricted cash, with total assets of 285,572 and stockholders’ equity of 174,864. Net cash used in operating activities improved to 3,739 for the first six months, from 12,440 in the prior-year period. Under a $30,000 share repurchase program authorized in February 2026, the company bought back and retired 1,145,150 shares for 7,498, leaving 22,502 available under the authorization.
Inogen, Inc. reported total revenue of $85.1 million for the quarter ended March 31, 2026, up 3.4% from $82.3 million a year earlier. Sales revenue rose to $72.4 million, driven mainly by stronger international demand, while rental revenue declined to $12.7 million due to fewer patients on service.
Gross margin held roughly steady at 44.5%, but operating expenses increased across research and development, sales and marketing, and general and administrative, leading to a larger net loss of $8.3 million, or $0.30 per share. Inogen ended the quarter with $93.1 million in cash and cash equivalents and used $6.7 million in operating cash. The company also began a share repurchase program, buying back 298,100 shares for about $1.9 million.
Inogen, Inc. (INGN) reported Q3 2025 results with total revenue of $92.4 million, up from $88.8 million a year ago. Net loss was $5.3 million and diluted loss per share was $0.20. Gross profit was $41.3 million, essentially flat year over year, as higher sales were offset by rental margin pressure.
Operating expenses fell modestly, narrowing the loss from operations to $7.1 million from $7.8 million. For the nine months, revenue reached $266.9 million with a net loss of $15.6 million, an improvement from $26.1 million last year.
Liquidity remained solid with cash and cash equivalents of $106.5 million and marketable securities of $16.7 million. Operating cash flow was an outflow of $10.3 million year to date. The company received $27.2 million from a common stock private placement at $10.36 per share in Q1 and paid a $13.0 million acquisition earnout. In August, Inogen settled the APT dispute for $1.75 million plus $0.67 million in legal costs. Shares outstanding were 27,148,482 as of October 31, 2025.
Inogen, Inc. reported consolidated second-quarter revenue of $92.3 million, up 4.0% year-over-year, driven by higher sales revenue of $79.2 million as unit shipments rose to ~49,000 systems versus ~41,300 a year earlier. Rental revenue declined 8.6% to $13.1 million, reflecting a shift toward lower private-payor reimbursement.
Gross margin narrowed to 44.8% from 48.1%, attributed to customer/channel mix and higher materials costs including semiconductor premiums. The company reported a net loss of $4.152 million in Q2 and a six-month loss of $10.326 million, while operating activities used $12.44 million of cash year-to-date. Liquidity remained solid with cash and cash equivalents of $103.7 million and total cash, cash equivalents and restricted cash of $104.96 million.
Corporate developments included a $27.21 million private placement with Yuwell, a Strategic Collaboration Agreement with Yuwell to broaden product distribution and accelerate Chinese market entry, and completion of earnout payments related to the Physio-Assist acquisition. Management is evaluating recent U.S. tax legislation and continues to record a valuation allowance on deferred tax assets.